TenX

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 14, 2024
TenX, Shareholder, Catheter, Accounting, Research, FDA, Food, Hemorrhoid, BLA, Calendar, PDUFA, FIRST, G&A, Pharmaceutical industry

CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended December 31, 2023.

Key Points: 
  • "We had a strong first quarter of fiscal 2024 during which we achieved multiple mission critical goals.
  • FIRST QUARTER 2024 Financial Results:
    As of December 31, 2023, the Company had $20.3 million in cash and cash equivalents.
  • R&D expenses were $2.6 million for the first quarter ended December 31, 2023, compared to $3.4 million for the first quarter ended December 31, 2022.
  • G&A expenses were $3.7 million for the first quarter ended December 31, 2023, compared to $2.6 million for the first quarter ended December 31, 2022.

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

Retrieved on: 
Wednesday, January 10, 2024
TenX, Meeting, Extension, Contribution, Date, Security (finance)

Each Contribution will be deposited in the Company’s trust account on or prior to the date of the applicable deadline.

Key Points: 
  • Each Contribution will be deposited in the Company’s trust account on or prior to the date of the applicable deadline.
  • Any Contribution is conditioned upon the implementation of the Extension Amendment Proposal.
  • No Contribution will occur if the Extension Amendment Proposal is not approved.
  • If any such shareholders have questions or need assistance in connection with the Meeting, please contact the Company’s proxy solicitor, D.F.

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, January 2, 2024
TenX, Accounting, Food, BLA, Consultant, Research, FDA, PDUFA, Pivotal, Lidocaine, University, CRL, Masonic Cancer Center, Patient, Safety, G&A, Pharmaceutical industry

CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2023.

Key Points: 
  • With the Mino-Lok pivotal Phase 3 trial enrollment completed, we expect topline results to be available in the second quarter of 2024.
  • Full Year 2022 Financial Results:
    As of September 30, 2023, the Company had $26.5 million in cash and cash equivalents.
  • Option expense under the Citius Oncology stock plan was $1.97 million during the year ended September 30, 2023.
  • In fiscal year 2023, we granted options under the Citius Pharma and Citius Oncology stock plans to our new employees and additional options to other employees, our directors, and consultants.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on: 
Tuesday, October 24, 2023
TenX, READ, Suite, Food, Medication, Lexington Avenue, Auxiliary routes of Arkansas Highway 18, SPAC, Sale, Form, Acquisition, ONCE, CTCL, Patient, Person, Commerce, PD-1, Newbridge, Non-Hodgkin lymphoma, FDA, Biologics license application, Regulation of tobacco by the U.S. Food and Drug Administration, Prospectus, Peripheral T-cell lymphoma, Annual report, BLA, Security (finance), Pharmaceutical industry, Bank, Cryptocurrency, Citius, Altius, Fortius

CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition (“TenX”) (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Key Points: 
  • The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”).
  • Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology.
  • “We are very pleased to announce the proposed merger with Citius Oncology,” said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
  • In the transaction, all shares of Citius Pharma’s wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

Retrieved on: 
Wednesday, October 18, 2023
TenX, Sale, Sponsor, Bank, Property management

New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from October 18, 2023 to January 18, 2024, the Company has deposited into its trust account (the “Trust Account”) an aggregate of $660,000 (the “Extension Fee”), representing $0.10 per public share of the Company.

Key Points: 
  • New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from October 18, 2023 to January 18, 2024, the Company has deposited into its trust account (the “Trust Account”) an aggregate of $660,000 (the “Extension Fee”), representing $0.10 per public share of the Company.
  • The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the “Sponsor”), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor.
  • This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on: 
Tuesday, October 24, 2023
TenX, READ, Suite, Food, Medication, Lexington Avenue, Auxiliary routes of Arkansas Highway 18, SPAC, Sale, Form, Acquisition, ONCE, CTCL, Patient, Person, Commerce, PD-1, Newbridge, Non-Hodgkin lymphoma, FDA, Biologics license application, Regulation of tobacco by the U.S. Food and Drug Administration, Prospectus, Peripheral T-cell lymphoma, Annual report, BLA, Security (finance), Pharmaceutical industry, Bank, Generic drug, Citius, Altius, Fortius

CRANFORD, N.J. and NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ("TenX") (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. ("Citius Oncology"). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024. 

Key Points: 
  • The newly combined public company will be named Citius Oncology, Inc. ("Citius Oncology").
  • "We are very pleased to announce the proposed merger with Citius Oncology," said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
  • Pursuant to the proposed agreement, TenX will acquire Citius Pharma's wholly owned subsidiary via a merger, with the newly combined publicly traded company to be named Citius Oncology, Inc.
  • In the transaction, all shares of Citius Pharma's wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

Retrieved on: 
Tuesday, July 18, 2023
TenX, Sale, Sponsor, Property management

New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from July 18, 2023 to October 18, 2023, the Company has deposited into its trust account (the “Trust Account”) an aggregate of $660,000 (the “Extension Fee”), representing $0.10 per public share of the Company.

Key Points: 
  • New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from July 18, 2023 to October 18, 2023, the Company has deposited into its trust account (the “Trust Account”) an aggregate of $660,000 (the “Extension Fee”), representing $0.10 per public share of the Company.
  • The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the “Sponsor”), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor.
  • This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022

Retrieved on: 
Tuesday, December 6, 2022
TenX, Transfer, Acquisition, Sale, Prospectus, Exercise, Risk, SPAC, Unit, Security (finance)

Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “TENKU.” Any underlying ordinary shares and rights that are separated are expected to trade on the NASDAQ under the symbols “TENK” and “TENKR,” respectively.

Key Points: 
  • Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “TENKU.” Any underlying ordinary shares and rights that are separated are expected to trade on the NASDAQ under the symbols “TENK” and “TENKR,” respectively.
  • Holders of Units will need to have their brokers contact the Company's transfer agent, American Stock Transfer & Trust Company, in order to separate the holders’ Units into ordinary shares and rights.
  • This press release contains statements that constitute “forward-looking statements,” including with respect to the separation and trading of the Company’s securities and search for an initial business combination.
  • TenX Keane Acquisition undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option

Retrieved on: 
Tuesday, October 18, 2022
TenX, U.S. Securities and Exchange Commission, Sale, Cayman Islands, SEC, SEC filing, NASDAQ, Park Avenue, Nasdaq, Company, Acquisition, Exercise, SPAC, Form, GLOBE, Prospectus, Forward-looking statement, Risk, Financial services, Security (finance)

Each right entitles the holder thereof to receive two-tenths (2/10) of one ordinary share upon consummation of the Companys initial business combination.

Key Points: 
  • Each right entitles the holder thereof to receive two-tenths (2/10) of one ordinary share upon consummation of the Companys initial business combination.
  • The units began trading on the Nasdaq Global Market (Nasdaq) under the ticker symbol TENKU on October 14, 2022.
  • This press release contains statements that constitute forward-looking statements, including with respect to the Companys search for an initial business combination.
  • The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering

Retrieved on: 
Thursday, October 13, 2022
TenX, U.S. Securities and Exchange Commission, Sale, Registration statement, SEC, SEC filing, Register, Form S-1, Park Avenue, Nasdaq, Company, Acquisition, SPAC, Form, GLOBE, Prospectus, Forward-looking statement, Risk, Security (finance)

Each right entitles the holder thereof to receive two-tenths (2/10) of one ordinary share upon consummation of the Companys initial business combination.

Key Points: 
  • Each right entitles the holder thereof to receive two-tenths (2/10) of one ordinary share upon consummation of the Companys initial business combination.
  • The units are expected to trade on the Nasdaq Global Market (Nasdaq) under the ticker symbol TENKU beginning on October 14, 2022.
  • The Company has granted the underwriter a 45-day option to purchase up to 900,000 additional units at the initial public offering price to cover over-allotments, if any.
  • This press release contains statements that constitute forward-looking statements, including with respect to the Companys initial public offering and search for an initial business combination.